Status:

COMPLETED

Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Lead Sponsor:

Abbott

Conditions:

Crohn's Disease

Eligibility:

All Genders

18-75 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well...

Detailed Description

This is an open-label, multi-center, study designed to evaluate the safety and efficacy of adalimumab on inducing and maintaining clinical remission in subjects with moderate to severe Crohn's Disease...

Eligibility Criteria

Inclusion

  • Diagnosis of moderate to severe Crohn's Disease confirmed by endoscopy or radiologic evaluation for greater than 4 months (16 weeks)
  • Inadequate response to conventional therapy for Crohn's Disease
  • Subjects \>=18 and \<=75 years of age and in good health (Investigator discretion) with a recent stable medical history
  • Harvey Bradshaw Index score of 7 or higher

Exclusion

  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Previous treatment with adalimumab or previous participation in an adalimumab clinical study
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Subjects with any prior exposure to Tysabri® (natalizumab)
  • Subjects on prednisone \>40 mg/day (or equivalent), subjects on budesonide \>9 mg/day, or subjects who are taking prednisone and budesonide concurrently at Baseline

Key Trial Info

Start Date :

December 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2008

Estimated Enrollment :

945 Patients enrolled

Trial Details

Trial ID

NCT00409617

Start Date

December 1 2006

End Date

July 1 2008

Last Update

October 10 2011

Active Locations (189)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 48 (189 locations)

1

Site Ref # / Investigator 3077

Graz, Austria, 8036

2

Site Ref # / Investigator 2978

Vienna, Austria, 1030

3

Site Ref # / Investigator 2975

Vienna, Austria, 1060

4

Site Ref # / Investigator 2976

Vienna, Austria, 1090